Ocular Therapeutix, Inc (OCUL): Depreciation & Amortization
$4.32M
Year ended 2025-12-31
$5.45M
Trailing 12 months to 2026-06-30
+27.0%
3-year compound annual growth
+9.3%
5-year compound annual growth
+19.1%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.32M | +14.2% | 2026-02-05, From 2025-01-01 |
| 2024-12-31 | $3.79M | +26.9% | 2026-02-05, From 2024-01-01 |
| 2023-12-31 | $2.98M | +41.4% | 2026-02-05, From 2023-01-01 |
| 2022-12-31 | $2.11M | -12.9% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $2.42M | -12.7% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $2.77M | +9.6% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $2.53M | +10.7% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $2.29M | +40.7% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $1.62M | +84.4% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $881.0K | +16.8% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $754.0K | +37.8% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $547.0K | +35.4% | 2017-03-10, From 2014-01-01 |
| 2013-12-31 | $404.0K | 0.0% | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | $404.0K | n/a | 2015-03-20, From 2012-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $4.32M | +14.2% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $621.0K | +16.3% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $318.0K | +3.6% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $1.03M | -76.6% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $24.0K | -97.1% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $3.93M | -26.9% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.28M | +55.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $1.60M | +14.3% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $548.0K | -23.7% |
Compare OCUL, LXRX, INBP, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗